Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07700979 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Name: Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma — clinical trial record (NCT07700979)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: G/GEJ

StatusRecruiting

PhasePhase 3

SponsorAkeso

Started2026-09-24

View on ClinicalTrials.gov ↗

Amendment history

2026-09-30

Recruitment opened

Akeso

96 trials monitored

See 1 trial at risk

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.

Trial Details

NCT Number	NCT07700979
Lead Sponsor	Akeso
Conditions	Gastric / Gastroesophageal Junction Adenocarcinoma
Enrollment	900 participants
Start Date	2026-09-24
Primary Completion	2029-08-18 (estimated)
Study Completion	2030-08-18 (estimated)
Updated on ClinicalTrials.gov	2026-09-29